These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 19452316)

  • 41. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma.
    Piro LD; White CA; Grillo-López AJ; Janakiraman N; Saven A; Beck TM; Varns C; Shuey S; Czuczman M; Lynch JW; Kolitz JE; Jain V
    Ann Oncol; 1999 Jun; 10(6):655-61. PubMed ID: 10442187
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
    Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE
    Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The role of the FcGRIIIa polymorphism in modifying the association between treatment and outcome in patients with rheumatoid arthritis treated with rituximab versus TNF-α antagonist therapies.
    Sarsour K; Greenberg J; Johnston JA; Nelson DR; O'Brien LA; Oddoux C; Ostrer H; Pearlman A; Reed G
    Clin Exp Rheumatol; 2013; 31(2):189-94. PubMed ID: 23294992
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Genetic polymorphisms of FcγRIIa and FcγRIIIa are not predictive of clinical outcomes after cetuximab plus irinotecan chemotherapy in patients with metastatic colorectal cancer.
    Park SJ; Hong YS; Lee JL; Ryu MH; Chang HM; Kim KP; Ahn YC; Na YS; Jin DH; Yu CS; Kim JC; Kang YK; Kim TW
    Oncology; 2012; 82(2):83-9. PubMed ID: 22327884
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Monoclonal antibodies capable of discriminating the human inhibitory Fcgamma-receptor IIB (CD32B) from the activating Fcgamma-receptor IIA (CD32A): biochemical, biological and functional characterization.
    Veri MC; Gorlatov S; Li H; Burke S; Johnson S; Stavenhagen J; Stein KE; Bonvini E; Koenig S
    Immunology; 2007 Jul; 121(3):392-404. PubMed ID: 17386079
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Development of a drug-disease simulation model for rituximab in follicular non-Hodgkin's lymphoma.
    Ternant D; Hénin E; Cartron G; Tod M; Paintaud G; Girard P
    Br J Clin Pharmacol; 2009 Oct; 68(4):561-73. PubMed ID: 19843059
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Granulocyte-macrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: results of a phase II study.
    Cartron G; Zhao-Yang L; Baudard M; Kanouni T; Rouillé V; Quittet P; Klein B; Rossi JF
    J Clin Oncol; 2008 Jun; 26(16):2725-31. PubMed ID: 18427151
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Absolute lymphocyte count predicts therapeutic efficacy of rituximab therapy in follicular lymphomas.
    Behl D; Ristow K; Markovic SN; Witzig TE; Habermann TM; Colgan JP; Inwards DJ; White WL; Ansell SM; Micallef IN; Johnston PB; Porrata LF
    Br J Haematol; 2007 Jun; 137(5):409-15. PubMed ID: 17433025
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment.
    Davis TA; Grillo-López AJ; White CA; McLaughlin P; Czuczman MS; Link BK; Maloney DG; Weaver RL; Rosenberg J; Levy R
    J Clin Oncol; 2000 Sep; 18(17):3135-43. PubMed ID: 10963642
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Fc gamma receptor glycosylation modulates the binding of IgG glycoforms: a requirement for stable antibody interactions.
    Hayes JM; Frostell A; Cosgrave EF; Struwe WB; Potter O; Davey GP; Karlsson R; Anneren C; Rudd PM
    J Proteome Res; 2014 Dec; 13(12):5471-85. PubMed ID: 25345863
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase I study of LY2469298, an Fc-engineered humanized anti-CD20 antibody, in patients with relapsed or refractory follicular lymphoma.
    Tobinai K; Ogura M; Kobayashi Y; Uchida T; Watanabe T; Oyama T; Maruyama D; Suzuki T; Mori M; Kasai M; Cronier D; Wooldridge JE; Koshiji M
    Cancer Sci; 2011 Feb; 102(2):432-8. PubMed ID: 21205069
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The effect of Rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK).
    Ghielmini M; Schmitz SF; Bürki K; Pichert G; Betticher DC; Stupp R; Wernli M; Lohri A; Schmitter D; Bertoni F; Cerny T
    Ann Oncol; 2000; 11 Suppl 1():123-6. PubMed ID: 10707793
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship.
    Dall'Ozzo S; Tartas S; Paintaud G; Cartron G; Colombat P; Bardos P; Watier H; Thibault G
    Cancer Res; 2004 Jul; 64(13):4664-9. PubMed ID: 15231679
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma.
    Freedman A; Neelapu SS; Nichols C; Robertson MJ; Djulbegovic B; Winter JN; Bender JF; Gold DP; Ghalie RG; Stewart ME; Esquibel V; Hamlin P
    J Clin Oncol; 2009 Jun; 27(18):3036-43. PubMed ID: 19414675
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism.
    Niwa R; Hatanaka S; Shoji-Hosaka E; Sakurada M; Kobayashi Y; Uehara A; Yokoi H; Nakamura K; Shitara K
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6248-55. PubMed ID: 15448014
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Retreatment with rituximab in 178 patients with relapsed and refractory B-cell lymphomas: a single institution case control study.
    Johnston A; Bouafia-Sauvy F; Broussais-Guillaumot F; Michallet AS; Traullé C; Salles G; Coiffier B
    Leuk Lymphoma; 2010 Mar; 51(3):399-405. PubMed ID: 20038227
    [TBL] [Abstract][Full Text] [Related]  

  • 57. FcγR polymorphisms and clinical outcome in colorectal cancer patients receiving passive or active antibody treatment.
    Wang B; Kokhaei P; Mellstedt H; Liljefors M
    Int J Oncol; 2010 Dec; 37(6):1599-606. PubMed ID: 21042730
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma.
    Tuscano JM; Dutia M; Chee K; Brunson A; Reed-Pease C; Abedi M; Welborn J; O'Donnell RT
    Br J Haematol; 2014 May; 165(3):375-81. PubMed ID: 24606326
    [TBL] [Abstract][Full Text] [Related]  

  • 59. FcγRIIA and FcγRIIIA polymorphisms do not influence survival and response to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy in patients with diffuse large B-cell lymphoma.
    Fabisiewicz A; Paszkiewicz-Kozik E; Osowiecki M; Walewski J; Siedlecki JA
    Leuk Lymphoma; 2011 Aug; 52(8):1604-6. PubMed ID: 21657954
    [No Abstract]   [Full Text] [Related]  

  • 60. Platelet-associated antibodies, cellular immunity and FCGR3a genotype influence the response to rituximab in immune thrombocytopenia.
    Cooper N; Stasi R; Cunningham-Rundles S; Cesarman E; McFarland JG; Bussel JB
    Br J Haematol; 2012 Aug; 158(4):539-47. PubMed ID: 22775462
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.